Recursion Pharmaceuticals $300 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by Recursion Pharmaceuticals, Inc. of its Class A common stock for up to an aggregate amount of $300 million. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol “RXRX.”
Recursion Pharmaceuticals is a clinical-stage biotechnology company industrializing drug discovery by decoding biology. Recursion is headquartered in Salt Lake City, Utah.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye and Rong (Fiona) Huang. The intellectual property team included partner Frank J. Azzopardi and associates S. Dream Montgomery and Annie Xie. Partner Mario J. Verdolini and associate Charles Collier provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.